Clinical trial
Lofexidine for Opiate Withdrawal - 1
NCT00032942 · National Institute on Drug Abuse (NIDA), NIH · Completed
Key facts
| NCT number | NCT00032942 |
|---|---|
| Title | Lofexidine for Opiate Withdrawal - 1 |
| Official title | A Phase III Placebo-Controlled, Double-Blind Multi-Site Trial of Lofexidine for Opiate Withdrawal |
| Lead sponsor | National Institute on Drug Abuse (NIDA), NIH |
| Collaborators | Britannia Pharmaceuticals Ltd. Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Opioid-Related Disorders |
| Intervention type | Drug |
| Interventions | Lofexidine |
| Enrollment | 66 |
| Start date | Apr 1, 2001 |
| Primary completion | Oct 1, 2004 |
| First posted | Apr 8, 2002 |
| Last update posted | Jan 12, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: